Skip to main content
Top
Published in: Medical Oncology 12/2016

01-12-2016 | Letter to the Editor

Tumor lysis syndrome and metastatic melanoma

Authors: Marshall W. Meeks, Muhammad B. Hammami, Katherine J. Robbins, Kevin L. Cheng, Jack M. Lionberger

Published in: Medical Oncology | Issue 12/2016

Login to get access

Abstract

Tumor lysis syndrome (TLS) is a potential emergent complication of oncologic treatment. TLS is commonly reported in hematological malignancies with rapid cell turnover rates, but is relatively rare in solid tumors. TLS is most frequently a result of cancer treatment in combination with a large tumor burden, but has occasionally been reported to occur spontaneously, especially in cases of advanced or metastatic disease. In this article, we describe the case of a patient with newly diagnosed metastatic melanoma that developed TLS two days after initiation of corticosteroids. In addition, we present a brief literature review of melanoma-associated TLS and review the etiology, diagnosis, and management of TLS.
Literature
7.
go back to reference Busam KJ, Wolchok J, Jungbluth AA, Chapman P. Diffuse melanosis after chemotherapy-induced tumor lysis syndrome in a patient with metastatic melanoma. J Cutan Pathol. 2004;31(3):274–80.CrossRefPubMed Busam KJ, Wolchok J, Jungbluth AA, Chapman P. Diffuse melanosis after chemotherapy-induced tumor lysis syndrome in a patient with metastatic melanoma. J Cutan Pathol. 2004;31(3):274–80.CrossRefPubMed
8.
go back to reference Castro MP, VanAuken J, Spencer-Cisek P, Legha S, Sponzo RW. Acute tumor lysis syndrome associated with concurrent biochemotherapy of metastatic melanoma: a case report and review of the literature. Cancer. 1999;85(5):1055–9.CrossRefPubMed Castro MP, VanAuken J, Spencer-Cisek P, Legha S, Sponzo RW. Acute tumor lysis syndrome associated with concurrent biochemotherapy of metastatic melanoma: a case report and review of the literature. Cancer. 1999;85(5):1055–9.CrossRefPubMed
9.
go back to reference Dar L, Gendelman O, Amital H. Tumor lysis syndrome presenting in a patient with metastatic melanoma treated with radiation therapy. Isr Med Assoc J. 2014;16(7):456–7.PubMed Dar L, Gendelman O, Amital H. Tumor lysis syndrome presenting in a patient with metastatic melanoma treated with radiation therapy. Isr Med Assoc J. 2014;16(7):456–7.PubMed
10.
go back to reference Habib GS, Saliba WR. Tumor lysis syndrome after hydrocortisone treatment in metastatic melanoma: a case report and review of the literature. Am J Med Sci. 2002;323(3):155–7.CrossRefPubMed Habib GS, Saliba WR. Tumor lysis syndrome after hydrocortisone treatment in metastatic melanoma: a case report and review of the literature. Am J Med Sci. 2002;323(3):155–7.CrossRefPubMed
11.
go back to reference Minasian LM, Szatrowski TP, Rosenblum M, Steffens T, Morrison ME, Chapman PB, et al. Hemorrhagic tumor necrosis during a pilot trial of tumor necrosis factor-alpha and anti-GD3 ganglioside monoclonal antibody in patients with metastatic melanoma. Blood. 1994;83(1):56–64.PubMed Minasian LM, Szatrowski TP, Rosenblum M, Steffens T, Morrison ME, Chapman PB, et al. Hemorrhagic tumor necrosis during a pilot trial of tumor necrosis factor-alpha and anti-GD3 ganglioside monoclonal antibody in patients with metastatic melanoma. Blood. 1994;83(1):56–64.PubMed
12.
go back to reference Stoves J, Richardson D, Patel H. Tumour lysis syndrome in a patient with metastatic melanoma treated with biochemotherapy. Nephrol Dial Transpl. 2001;16(1):188–9.CrossRef Stoves J, Richardson D, Patel H. Tumour lysis syndrome in a patient with metastatic melanoma treated with biochemotherapy. Nephrol Dial Transpl. 2001;16(1):188–9.CrossRef
Metadata
Title
Tumor lysis syndrome and metastatic melanoma
Authors
Marshall W. Meeks
Muhammad B. Hammami
Katherine J. Robbins
Kevin L. Cheng
Jack M. Lionberger
Publication date
01-12-2016
Publisher
Springer US
Published in
Medical Oncology / Issue 12/2016
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-016-0854-5

Other articles of this Issue 12/2016

Medical Oncology 12/2016 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.